Aurobindo Pharma Shares Dip on Weak Outlook

  Published 1 year ago

Aurobindo Pharma shares fell over 2% after reporting a slight Q4 profit dip and forecasting flat FY26 margins. Concerns center around Revlimid competition, plant delays, and subsequent analyst downgrades and lowered estimates.

  • Q4 profit declined; FY26 margins flat.
  • Revlimid sales are expected to decrease.
  • Analysts cut price targets & downgraded.

You might like these

Adani Group Faces US Probe Over Iran LPG Imports

India Tightens FDI Rules for Foreign, Owned Firms

Amazon & FICO Partner for AI-Powered Decisions

Voltas Q1 Profit Falls 58%

Surat's Diamond Trade Faces Uncertainty

India & Kyrgyzstan Strengthen Investment Ties

Gold Financiers Rally on RBI Loan Rule Relaxation

News that matters the most ⚡